Visfatin/PBEF/Nampt: A New Cardiovascular Target?

In the last years, a growing interest has emerged toward understanding the role of adipocytokines in the development of cardio-metabolic complications. Five years ago, visfatin/PBEF/Nampt was identified as a novel adipocytokine. In the context of metabolic disorders, extracellular visfatin/PBEF/Namp...

Full description

Bibliographic Details
Main Authors:	Peiró, Concepción, Romacho, Tania, Carraro, Raffaele, Sánchez-Ferrer, Carlos F.
Format:	Online
Language:	English
Published:	Frontiers Research Foundation 2010
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153009/

id	pubmed-3153009
recordtype	oai_dc
spelling	pubmed-31530092011-08-10 Visfatin/PBEF/Nampt: A New Cardiovascular Target? Peiró, Concepción Romacho, Tania Carraro, Raffaele Sánchez-Ferrer, Carlos F. Pharmacology In the last years, a growing interest has emerged toward understanding the role of adipocytokines in the development of cardio-metabolic complications. Five years ago, visfatin/PBEF/Nampt was identified as a novel adipocytokine. In the context of metabolic disorders, extracellular visfatin/PBEF/Nampt was initially claimed as a potentially beneficial molecule due to its insulin-mimetic and glucose-lowering properties. Nevertheless, growing evidence has since then unveiled that visfatin/PBEF/Nampt may rather be a biomarker of inflammation and endothelial damage, and also a direct regulator of the cardiovascular system that modulates cell proliferation and survival, extracellular matrix, vascular reactivity, and inflammation. On one side, the blockade of the deleterious cardiovascular actions of visfatin/PBEF/Nampt is being regarded as a potential approach to prevent and treat, not only cardio-metabolic complications, but also other pathologies implying excessive angiogenesis. Conversely, the administration of visfatin/PBEF/Nampt has shown beneficial effects in different ischemic conditions. Further research is required to evaluate the real value of visfatin/PBEF/Nampt as a pharmacological target. Frontiers Research Foundation 2010-11-23 /pmc/articles/PMC3153009/ /pubmed/21833174 http://dx.doi.org/10.3389/fphar.2010.00135 Text en Copyright © 2010 Peiró, Romacho, Carraro and Sánchez-Ferrer. http://www.frontiersin.org/licenseagreement This is an open-access article subject to an exclusive license agreement between the authors and the Frontiers Research Foundation, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Peiró, Concepción Romacho, Tania Carraro, Raffaele Sánchez-Ferrer, Carlos F.
spellingShingle	Peiró, Concepción Romacho, Tania Carraro, Raffaele Sánchez-Ferrer, Carlos F. Visfatin/PBEF/Nampt: A New Cardiovascular Target?
author_facet	Peiró, Concepción Romacho, Tania Carraro, Raffaele Sánchez-Ferrer, Carlos F.
author_sort	Peiró, Concepción
title	Visfatin/PBEF/Nampt: A New Cardiovascular Target?
title_short	Visfatin/PBEF/Nampt: A New Cardiovascular Target?
title_full	Visfatin/PBEF/Nampt: A New Cardiovascular Target?
title_fullStr	Visfatin/PBEF/Nampt: A New Cardiovascular Target?
title_full_unstemmed	Visfatin/PBEF/Nampt: A New Cardiovascular Target?
title_sort	visfatin/pbef/nampt: a new cardiovascular target?
description	In the last years, a growing interest has emerged toward understanding the role of adipocytokines in the development of cardio-metabolic complications. Five years ago, visfatin/PBEF/Nampt was identified as a novel adipocytokine. In the context of metabolic disorders, extracellular visfatin/PBEF/Nampt was initially claimed as a potentially beneficial molecule due to its insulin-mimetic and glucose-lowering properties. Nevertheless, growing evidence has since then unveiled that visfatin/PBEF/Nampt may rather be a biomarker of inflammation and endothelial damage, and also a direct regulator of the cardiovascular system that modulates cell proliferation and survival, extracellular matrix, vascular reactivity, and inflammation. On one side, the blockade of the deleterious cardiovascular actions of visfatin/PBEF/Nampt is being regarded as a potential approach to prevent and treat, not only cardio-metabolic complications, but also other pathologies implying excessive angiogenesis. Conversely, the administration of visfatin/PBEF/Nampt has shown beneficial effects in different ischemic conditions. Further research is required to evaluate the real value of visfatin/PBEF/Nampt as a pharmacological target.
publisher	Frontiers Research Foundation
publishDate	2010
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153009/
_version_	1611469958424821760

Visfatin/PBEF/Nampt: A New Cardiovascular Target?

Similar Items